U.S. Markets closed

Horizon Pharma Public Limited Company (HZNP)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
13.31+0.17 (+1.29%)
At close: 4:00PM EDT
People also watch
DEPOSRPTFOLDJUNORDUS

Horizon Pharma Public Limited Company

Connaught House
1st Floor
Dublin 4
Ireland
353 1 772 2100
http://www.horizonpharma.com

SectorHealthcare
IndustryDrugs - Generic
Full Time Employees935

Key Executives

NameTitlePayExercisedAge
Mr. Timothy P. WalbertChairman, Pres & Chief Exec. Officer2.28M172.93k50
Mr. Paul W. HoelscherChief Financial Officer and Exec. VP904.01kN/A52
Mr. Barry J. MozeChief Admin. Officer and Exec. VP951.55kN/A63
Mr. Robert F. CareyChief Bus. Officer and Exec. VP881.09kN/A58
Mr. David A. HappelExec. VP of Global Orphan Bus. Unit406.11kN/A55
Amounts are as of December 31, 2016 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Horizon Pharma Public Limited Company, a biopharmaceutical company, engages in identifying, developing, acquiring, and commercializing medicines for the treatment of orphan diseases, arthritis, pain, and inflammation and inflammatory diseases in the United States and internationally. The company’s marketed medicine portfolio consists of ACTIMMUNE for the treatment of chronic granulomatous disease and malignant osteopetrosis; RAVICTI and BUPHENYL/AMMONAPS to treat urea cycle disorders; PROCYSBI for the treatment of nephropathic cystinosis; QUINSAIR for the treatment of chronic pulmonary infections due to pseudomonas aeruginosa in cystic fibrosis patients; and KRYSTEXXA to treat chronic refractory gout. Its products also include RAYOS/LODOTRA for the treatment of rheumatoid arthritis, polymyalgia rheumatic, systemic lupus erythematosus, and multiple other indications; DUEXIS to treat signs and symptoms of osteoarthritis and rheumatoid arthritis; MIGERGOT for the treatment of vascular headache; PENNSAID 2% to treat pain of osteoarthritis of the knees; and VIMOVO for the treatment of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis. The company has collaboration agreements with Fox Chase Cancer Center to study ACTIMMUNE in combination with PD-1/PD-L1 inhibitors for use in the treatment of various forms of cancer; and Alliance for Lupus Research (ALR) to study the effect of RAYOS on the fatigue experienced by systemic lupus erythematosus (SLE) patients. Horizon Pharma Public Limited Company was founded in 2005 and is headquartered in Dublin, Ireland.

Corporate Governance

Horizon Pharma Public Limited Company’s ISS Governance QualityScore as of August 1, 2017 is 6. The pillar scores are Audit: 1; Board: 5; Shareholder Rights: 7; Compensation: 5.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.